Production of large quantities of recombinant adeno-associated virus (AAV) is difficult and not cost-effective.To overcome this problem, we have explored the feasibility of creating a recombinant AAV encoding a 6؋His tag on the VP3 capsid protein. We generated a plasmid vector containing a six-His (6؋His)-tagged AAV VP3. A second plasmid vector was generated that contained the full-length AAV capsid capable of producing VP1 and VP2, but not VP3 due to a mutation at position 2809 that encodes the start codon for VP3. These plasmids, necessary for production of AAV, were transfected into 293 cells to generate a 6؋His-tagged VP3mutant recombinant AAV. The 6؋His-tagged VP3 did not affect the formation of AAV virus, and the physical properties of the 6؋His-modified AAV were equivalent to those of wild-type particles. The 6؋His-tagged AAV did not affect the production titer of recombinant AAV and could be used to purify the recombinant AAV using an Ni-nitrilotriacetic acid column. Addition of the 6؋His tag did not alter the viral tropism compared to wild-type AAV. These observations demonstrate the feasibility of producing high-titer AAV containing a 6؋His-tagged AAV VP3 capsid protein and to utilize the 6؋His-tagged VP3 capsid to achieve high-affinity purification of this recombinant AAV.Adeno-associated virus (AAV) capsids are composed of three proteins, VP1, VP2, and VP3 (4, 13-15, 32). Packaged within the capsid is a single-stranded DNA genome of 4,679 bases that contains two large open reading frames (ORFs), rep and cap (27). The three structural proteins, VP1 (87-kDa), VP2 (73-kDa), and VP3 (62-kDa), are encoded by a single ORF. Each of them are produced by alternative splicing of the transcript generated from the p40 promoter by use of alternative start codons at nucleotide position 2203 for VP1, 2614 for VP2, and 2809 for VP3 (15,31,32). The C-terminal region sequences that are common to all three capsid proteins promote folding of the C-terminal region of the polypeptide into a -barrel structure, which is present in several viruses, including parvovirus B19 and porcine parvovirus (1,5,7,18,19,26). The relative abundance of VP3 within the capsid is considerably higher (90%), than that of VP1 (5%) and VP2 (5%) (24,29,32).Recently, AAV has attracted a significant amount of interest as a vector for gene therapy (28). AAV has a number of unique advantages that are potentially useful for gene therapy applications, including the ability to infect nondividing cells, a lack of pathogenicity, and the ability to establish long-term gene expression (16,17). Attempts to alter the AAV capsid have been made in order to expand the tropism of AAV. Yang et al. (34) showed improved infectivity of hematopoietic progenitor cells by generating a chimeric recombinant AAV (rAAV) containing a single-chain antibody with specificity for human CD34. Girod et al. (11) showed that insertion of the L14 epitope into the capsid coding region can expand the tropism to mouse melanoma cell B16 cells that are nonpermissive for AAV infection....